GMAB
55.78 USD
-1.19%
Today
-0.23%
1D
Market is closed
Sun
Closed
Mon
4:30 PM ~ 10:59 PM
Tue
4:30 PM ~ 10:59 PM
Wed
4:30 PM ~ 10:59 PM
Thu
4:30 PM ~ 10:59 PM
Fri
4:30 PM ~ 10:59 PM
Sat
Closed
Information
Name
Genmab A/S
Currency
USD
Market Cap
34.14B
Avg Daily Volume
3.99M
52 Week High
59.97 USD
52 Week Low
23.62 USD
Trading Hours
See hours
Business Summary
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Top News
Genmab
+1.67%
Genmab to Present Results from Comprehensive Epcoritamab Development Program Highlighting Potential Across B-Cell Malignancies at the 2026 American Society of Hematology (ASH) Annual Meeting
tradingview.com
43m ago
Genmab
+1.67%
EQT_Corp
-0.15%
RangeResou
-1.42%
Matador
-1.14%
Healthcare.Services
-1.13%
Devon
-1.68%
Remitly.Global
+1.77%
Cushman&Wakefield
+5.08%
Caseys
+0.71%
BootBarn
+6.25%
ScottsMiracle-Gro
+6.33%
RealReal
+1.69%
GE.Vernova
-7.33%
MP_Materials
-0.34%
Aehr.Systems
-5.87%
Amprius.Technologies
-1.35%
AmericanEx
+2.83%
LPL_Financial
+5.09%
Dave.Inc
-0.06%
Ecolab
+1.77%
APiGroup
+0.11%
CleanHarbors
+4.87%
Repligen
+5.10%
Curtiss-Wright
-1.32%
Generac
-4.58%
Novanta
+0.32%
OracleCorp
-2.47%
Everpure.Inc
-3.19%
Credo.Technology
-6.83%
UnitySoftware
+2.03%
Dynatrace
+0.21%
JonesLangLaSalle
-0.55%
Zeta.Global
+0.39%
William Blair refreshes stock Conviction List with 5 additions, 3 removals
tradingview.com
2d ago
Genmab
+1.67%
Weekly Recap: Petosemtamab cuts death risk 50% and Genmab eyes 2027
tradingview.com
2d ago
Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.
